Group 1: JNJ-77242113 Dose 1 for Psoriasis Vulgaris (Plaque Psoriasis)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Centrum Terapii Wspolczesnej J. M. Jasnorzewska Spolka Komandytowo-Akcyjna, Łódź, Poland
Psoriasis Vulgaris (Plaque Psoriasis)+1 More
JNJ-77242113 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of the study is to evaluate the efficacy of an oral tablet formulation of JNJ-77242113 compared with placebo in participants with moderate-to-severe plaque psoriasis.

Eligible Conditions

  • Psoriasis Vulgaris (Plaque Psoriasis)

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Psoriasis Vulgaris (Plaque Psoriasis)

Study Objectives

1 Primary · 8 Secondary · Reporting Duration: Up to Week 24

Baseline and Week 16
Change from Baseline in Body Surface Area (BSA) at Week 16
Change from Baseline in PASI Total Score at Week 16
Up to Week 24
Number of Participants with Adverse Events (AEs)
Number of Participants with Serious Adverse Events (SAEs)
Week 16
Percentage of Participants Achieving PASI 100 Score at Week 16
Percentage of Participants Achieving PASI 90 Score at Week 16
Percentage of Participants Achieving Psoriasis Area Severity Index (PASI) 75 Score at Week 16
Percentage of Participants Achieving an IGA Score of Cleared (0) at Week 16
Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) at Week 16

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Other trials for Psoriasis Vulgaris (Plaque Psoriasis)

Trial Design

3 Treatment Groups

Group 1: JNJ-77242113 Dose 1
1 of 3
Group 2: JNJ-77242113 Dose 2
1 of 3
Group 3: Placebo
1 of 3
Experimental Treatment
Non-Treatment Group

80 Total Participants · 3 Treatment Groups

Primary Treatment: Group 1: JNJ-77242113 Dose 1 · Has Placebo Group · Phase 2

Group 1: JNJ-77242113 Dose 1
Drug
Experimental Group · 1 Intervention: JNJ-77242113 · Intervention Types: Drug
Group 2: JNJ-77242113 Dose 2
Drug
Experimental Group · 1 Intervention: JNJ-77242113 · Intervention Types: Drug
Group 3: Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to week 24
Closest Location: ActivMed Practices & Research · Portsmouth, NH
2011First Recorded Clinical Trial
1 TrialsResearching Psoriasis Vulgaris (Plaque Psoriasis)
16 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have plaque psoriasis, with or without psoriatic arthritis, for at least 26 weeks prior to the first administration of study intervention.
You have a BSA greater than or equal to (>=) 10% at baseline and/or screening.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.